Riverstone Advisors LLC Buys 160 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Riverstone Advisors LLC boosted its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 28.1% in the third quarter, Holdings Channel reports. The firm owned 730 shares of the medical equipment provider’s stock after acquiring an additional 160 shares during the period. Riverstone Advisors LLC’s holdings in Intuitive Surgical were worth $359,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ISRG. Vanguard Group Inc. lifted its stake in shares of Intuitive Surgical by 1.6% in the first quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock worth $12,319,358,000 after buying an additional 493,126 shares during the last quarter. Capital World Investors boosted its holdings in Intuitive Surgical by 1.0% during the first quarter. Capital World Investors now owns 7,284,269 shares of the medical equipment provider’s stock valued at $2,907,079,000 after acquiring an additional 73,634 shares during the period. American Century Companies Inc. increased its stake in shares of Intuitive Surgical by 3.0% in the second quarter. American Century Companies Inc. now owns 2,398,193 shares of the medical equipment provider’s stock worth $1,066,837,000 after purchasing an additional 70,556 shares during the period. Clearbridge Investments LLC lifted its position in shares of Intuitive Surgical by 1.6% during the 2nd quarter. Clearbridge Investments LLC now owns 1,981,297 shares of the medical equipment provider’s stock worth $881,380,000 after purchasing an additional 30,449 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its stake in Intuitive Surgical by 15.4% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,483,406 shares of the medical equipment provider’s stock valued at $659,893,000 after purchasing an additional 197,841 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Price Performance

Shares of NASDAQ:ISRG opened at $536.45 on Friday. The business’s fifty day moving average price is $493.92 and its two-hundred day moving average price is $451.73. Intuitive Surgical, Inc. has a fifty-two week low of $269.49 and a fifty-two week high of $538.49. The stock has a market capitalization of $191.07 billion, a price-to-earnings ratio of 86.25, a price-to-earnings-growth ratio of 5.07 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.24 by $0.32. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%. The business had revenue of $2.04 billion for the quarter, compared to analyst estimates of $2.01 billion. Research analysts expect that Intuitive Surgical, Inc. will post 5.45 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Robert Desantis sold 188 shares of Intuitive Surgical stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $482.21, for a total value of $90,655.48. Following the completion of the transaction, the executive vice president now owns 5,506 shares in the company, valued at approximately $2,655,048.26. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, EVP Robert Desantis sold 188 shares of the firm’s stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $482.21, for a total value of $90,655.48. Following the completion of the sale, the executive vice president now directly owns 5,506 shares in the company, valued at approximately $2,655,048.26. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Gary S. Guthart sold 18,151 shares of Intuitive Surgical stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $511.63, for a total value of $9,286,596.13. Following the completion of the transaction, the chief executive officer now directly owns 24,219 shares of the company’s stock, valued at $12,391,166.97. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 68,246 shares of company stock valued at $33,839,308. 0.90% of the stock is currently owned by insiders.

Analyst Ratings Changes

ISRG has been the topic of several recent analyst reports. Oppenheimer reaffirmed a “market perform” rating on shares of Intuitive Surgical in a research report on Friday, October 18th. Stifel Nicolaus upped their target price on shares of Intuitive Surgical from $475.00 to $525.00 and gave the company a “buy” rating in a research note on Friday, October 18th. BTIG Research set a $535.00 price target on shares of Intuitive Surgical in a report on Friday, October 18th. Barclays boosted their price objective on shares of Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a report on Thursday, July 18th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $538.00 target price (up previously from $495.00) on shares of Intuitive Surgical in a research note on Friday, October 18th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat, Intuitive Surgical presently has an average rating of “Moderate Buy” and a consensus target price of $513.74.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.